Stem definition | Drug id | CAS RN |
---|---|---|
924 | 58-32-2 |
Dose | Unit | Route |
---|---|---|
0.40 | g | O |
0.20 | g | P |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 0.01 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 0.10 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 13.21 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 50 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 0.82 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 2 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.01 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 13 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Dec. 6, 1961 | FDA | BOEHRINGER INGELHEIM |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Sedation complication | 282.18 | 14.89 | 78 | 9926 | 3567 | 46672491 |
Cerebrovascular accident | 226.27 | 14.89 | 181 | 9823 | 100858 | 46575200 |
Orthostatic hypotension | 220.68 | 14.89 | 107 | 9897 | 24551 | 46651507 |
Creatinine renal clearance decreased | 213.18 | 14.89 | 73 | 9931 | 6847 | 46669211 |
Sedation | 209.80 | 14.89 | 101 | 9903 | 22809 | 46653249 |
Cognitive disorder | 198.72 | 14.89 | 114 | 9890 | 36769 | 46639289 |
Blood calcium decreased | 167.82 | 14.89 | 77 | 9927 | 15596 | 46660462 |
Balance disorder | 128.28 | 14.89 | 108 | 9896 | 64413 | 46611645 |
Depressed level of consciousness | 127.61 | 14.89 | 95 | 9909 | 47474 | 46628584 |
Transient ischaemic attack | 114.97 | 14.89 | 79 | 9925 | 34824 | 46641234 |
Constipation | 85.67 | 14.89 | 142 | 9862 | 173955 | 46502103 |
Fall | 79.85 | 14.89 | 200 | 9804 | 328897 | 46347161 |
Mobility decreased | 69.71 | 14.89 | 75 | 9929 | 60519 | 46615539 |
Hypotension | 55.89 | 14.89 | 141 | 9863 | 232448 | 46443610 |
Drug ineffective | 49.22 | 14.89 | 44 | 9960 | 677794 | 45998264 |
Cerebral infarction | 42.06 | 14.89 | 37 | 9967 | 23329 | 46652729 |
Subdural haematoma | 39.44 | 14.89 | 28 | 9976 | 12969 | 46663089 |
Extradural haematoma | 28.75 | 14.89 | 11 | 9993 | 1412 | 46674646 |
Embolism | 25.48 | 14.89 | 17 | 9987 | 7121 | 46668937 |
Rheumatoid arthritis | 25.18 | 14.89 | 10 | 9994 | 240205 | 46435853 |
Neurological symptom | 23.92 | 14.89 | 14 | 9990 | 4665 | 46671393 |
Subarachnoid haemorrhage | 22.79 | 14.89 | 19 | 9985 | 11134 | 46664924 |
Fatigue | 21.09 | 14.89 | 64 | 9940 | 608633 | 46067425 |
Acute myocardial infarction | 19.75 | 14.89 | 29 | 9975 | 31895 | 46644163 |
Peripheral swelling | 19.35 | 14.89 | 5 | 9999 | 158066 | 46517992 |
Oesophageal ulcer haemorrhage | 19.30 | 14.89 | 6 | 9998 | 413 | 46675645 |
Gastrointestinal haemorrhage | 18.60 | 14.89 | 47 | 9957 | 77326 | 46598732 |
Nail ridging | 18.15 | 14.89 | 5 | 9999 | 225 | 46675833 |
Hyperlipidaemia | 17.95 | 14.89 | 21 | 9983 | 18518 | 46657540 |
Cerebral haemorrhage | 17.88 | 14.89 | 26 | 9978 | 28345 | 46647713 |
Headache | 17.73 | 14.89 | 168 | 9836 | 478184 | 46197874 |
Stress cardiomyopathy | 17.46 | 14.89 | 14 | 9990 | 7770 | 46668288 |
Mediastinal haemorrhage | 16.97 | 14.89 | 3 | 10001 | 15 | 46676043 |
Off label use | 16.96 | 14.89 | 35 | 9969 | 379806 | 46296252 |
Left ventricular end-diastolic pressure increased | 16.55 | 14.89 | 5 | 9999 | 313 | 46675745 |
Carotid artery occlusion | 16.41 | 14.89 | 9 | 9995 | 2650 | 46673408 |
Toxicity to various agents | 15.75 | 14.89 | 88 | 9916 | 211678 | 46464380 |
Joint swelling | 15.68 | 14.89 | 8 | 9996 | 166065 | 46509993 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Cerebrovascular accident | 266.28 | 13.49 | 208 | 8444 | 83269 | 29860557 |
Transient ischaemic attack | 129.07 | 13.49 | 84 | 8568 | 25116 | 29918710 |
Cerebral haemorrhage | 67.76 | 13.49 | 64 | 8588 | 32823 | 29911003 |
Headache | 45.15 | 13.49 | 135 | 8517 | 182171 | 29761655 |
Splenic injury | 32.16 | 13.49 | 6 | 8646 | 30 | 29943796 |
Peritoneal haematoma | 28.18 | 13.49 | 6 | 8646 | 64 | 29943762 |
Carotid artery occlusion | 24.85 | 13.49 | 12 | 8640 | 2013 | 29941813 |
Drug ineffective | 24.41 | 13.49 | 38 | 8614 | 340349 | 29603477 |
Loss of consciousness | 23.70 | 13.49 | 63 | 8589 | 79312 | 29864514 |
Cerebral infarction | 23.03 | 13.49 | 33 | 8619 | 26340 | 29917486 |
Gastrointestinal haemorrhage | 21.72 | 13.49 | 63 | 8589 | 83383 | 29860443 |
Vitreous haemorrhage | 21.44 | 13.49 | 11 | 8641 | 2099 | 29941727 |
Labelled drug-drug interaction medication error | 20.71 | 13.49 | 20 | 8632 | 10518 | 29933308 |
Aphasia | 19.49 | 13.49 | 26 | 8626 | 19413 | 29924413 |
Fine motor delay | 18.62 | 13.49 | 5 | 8647 | 150 | 29943676 |
Monocytosis | 18.34 | 13.49 | 6 | 8646 | 360 | 29943466 |
Embolic stroke | 18.33 | 13.49 | 12 | 8640 | 3610 | 29940216 |
Haemorrhage intracranial | 18.06 | 13.49 | 22 | 8630 | 15010 | 29928816 |
Off label use | 16.74 | 13.49 | 29 | 8623 | 249261 | 29694565 |
Tubulointerstitial nephritis | 16.53 | 13.49 | 23 | 8629 | 17868 | 29925958 |
Ocular myasthenia | 16.34 | 13.49 | 5 | 8647 | 241 | 29943585 |
Myalgia | 16.34 | 13.49 | 54 | 8598 | 76613 | 29867213 |
Haematemesis | 16.22 | 13.49 | 28 | 8624 | 26175 | 29917651 |
Intra-abdominal haemorrhage | 15.88 | 13.49 | 9 | 8643 | 2093 | 29941733 |
Hypotension | 15.50 | 13.49 | 105 | 8547 | 200460 | 29743366 |
Abdominal sepsis | 15.23 | 13.49 | 7 | 8645 | 1050 | 29942776 |
Lacunar infarction | 14.87 | 13.49 | 10 | 8642 | 3145 | 29940681 |
Diverticulitis intestinal haemorrhagic | 14.35 | 13.49 | 5 | 8647 | 364 | 29943462 |
Lip swelling | 14.26 | 13.49 | 18 | 8634 | 12726 | 29931100 |
Fatigue | 13.86 | 13.49 | 47 | 8605 | 320626 | 29623200 |
Dizziness | 13.86 | 13.49 | 100 | 8552 | 194809 | 29749017 |
Device related thrombosis | 13.71 | 13.49 | 6 | 8646 | 803 | 29943023 |
Hemiparesis | 13.63 | 13.49 | 19 | 8633 | 14783 | 29929043 |
Source | Code | Description |
---|---|---|
ATC | B01AC07 | BLOOD AND BLOOD FORMING ORGANS ANTITHROMBOTIC AGENTS ANTITHROMBOTIC AGENTS Platelet aggregation inhibitors excl. heparin |
FDA PE | N0000008832 | Decreased Platelet Aggregation |
FDA EPC | N0000175578 | Platelet Aggregation Inhibitor |
CHEBI has role | CHEBI:35620 | vasodilator |
CHEBI has role | CHEBI:50427 | platelet aggregation inhibitors |
CHEBI has role | CHEBI:50445 | adenosine deaminase inhibitors |
MeSH PA | D002317 | Cardiovascular Agents |
MeSH PA | D004791 | Enzyme Inhibitors |
MeSH PA | D006401 | Hematologic Agents |
MeSH PA | D010726 | Phosphodiesterase Inhibitors |
MeSH PA | D010975 | Platelet Aggregation Inhibitors |
MeSH PA | D014665 | Vasodilator Agents |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Chronic heart failure | indication | 48447003 | |
Atrial fibrillation | indication | 49436004 | DOID:0060224 |
Platelet Aggregation Inhibition | indication | ||
Prevention of Cerebral Thrombosis | indication | ||
Myocardial Perfusion Imaging Adjunct | indication | ||
Cerebral embolism | off-label use | 75543006 | DOID:4372 |
Transient ischemic attack | off-label use | 266257000 | DOID:224 |
Thromboembolic disorder | off-label use | 371039008 | |
Myocardial Reinfarction Prevention | off-label use | ||
Alcoholism | contraindication | 7200002 | |
Poisoning by digitalis glycoside | contraindication | 12876009 | |
Peptic ulcer | contraindication | 13200003 | DOID:750 |
Senile cardiac amyloidosis | contraindication | 16573007 | |
Myocardial infarction | contraindication | 22298006 | DOID:5844 |
Sick sinus syndrome | contraindication | 36083008 | DOID:13884 |
Gastrointestinal ulcer | contraindication | 40845000 | |
Myxedema | contraindication | 43153006 | DOID:11634 |
Hypokalemia | contraindication | 43339004 | |
Low blood pressure | contraindication | 45007003 | |
Sinus bradycardia | contraindication | 49710005 | |
Myocarditis | contraindication | 50920009 | DOID:820 |
Vitamin K deficiency | contraindication | 52675005 | DOID:11249 |
Nasal polyp | contraindication | 52756005 | |
Acute nephropathy | contraindication | 58574008 | |
Hypercalcemia | contraindication | 66931009 | DOID:12678 |
Ventricular fibrillation | contraindication | 71908006 | |
Factor II deficiency | contraindication | 73975000 | |
Reye's syndrome | contraindication | 74351001 | DOID:14525 |
Wolff-Parkinson-White pattern | contraindication | 74390002 | DOID:384 |
Gastrointestinal hemorrhage | contraindication | 74474003 | |
Thrombotic thrombocytopenic purpura | contraindication | 78129009 | DOID:10772 |
Cor pulmonale | contraindication | 83291003 | DOID:8515 |
Constrictive pericarditis | contraindication | 85598007 | DOID:11481 |
Gout | contraindication | 90560007 | DOID:13189 |
Kidney disease | contraindication | 90708001 | DOID:557 |
Hemophilia | contraindication | 90935002 | |
Anemia due to enzyme deficiency | contraindication | 111577008 | |
von Willebrand disorder | contraindication | 128105004 | DOID:12531 |
Hypomagnesemia | contraindication | 190855004 | |
Atrioventricular block | contraindication | 233917008 | DOID:0050820 |
Disease of liver | contraindication | 235856003 | DOID:409 |
Anemia | contraindication | 271737000 | DOID:2355 |
Pregnancy, function | contraindication | 289908002 | |
Thrombocytopenic disorder | contraindication | 302215000 | DOID:1588 |
Idiopathic hypertrophic subaortic stenosis | contraindication | 360465008 | |
Acute coronary syndrome | contraindication | 394659003 | |
Breastfeeding (mother) | contraindication | 413712001 | |
Restrictive cardiomyopathy | contraindication | 415295002 | DOID:397 |
Acute erosive gastritis | contraindication | 444926003 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 9.0 | Basic |
pKa2 | 8.52 | Basic |
pKa3 | 2.75 | Basic |
pKa4 | 2.12 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Phosphodiesterase 1 | Enzyme | INHIBITOR | IC50 | 4.35 | CHEMBL | CHEMBL | |||
cGMP-dependent 3',5'-cyclic phosphodiesterase | Enzyme | INHIBITOR | IC50 | 5.49 | CHEMBL | CHEMBL | |||
Phosphodiesterase 3 | Enzyme | INHIBITOR | IC50 | 4.37 | CHEMBL | CHEMBL | |||
cGMP-specific 3',5'-cyclic phosphodiesterase | Enzyme | INHIBITOR | IC50 | 6.28 | CHEMBL | CHEMBL | |||
cAMP-specific 3',5'-cyclic phosphodiesterase 4A | Enzyme | INHIBITOR | IC50 | 5.80 | DRUG MATRIX | CHEMBL | |||
cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A | Enzyme | INHIBITOR | Ki | 6 | CHEMBL | CHEMBL | |||
High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8A | Enzyme | INHIBITOR | IC50 | 5.10 | CHEMBL | CHEMBL | |||
High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8B | Enzyme | INHIBITOR | IC50 | 4.30 | IUPHAR | CHEMBL | |||
Equilibrative nucleoside transporter 1 | Transporter | INHIBITOR | Ki | 8.50 | CHEMBL | CHEMBL | |||
Phosphodiesterase 6 | Enzyme | INHIBITOR | Ki | 6.90 | CHEMBL | CHEMBL | |||
cAMP-specific 3',5'-cyclic phosphodiesterase 7B | Enzyme | INHIBITOR | IC50 | 6 | CHEMBL | CHEMBL | |||
Phosphodiesterase 7 | Enzyme | INHIBITOR | Ki | 6.22 | CHEMBL | CHEMBL | |||
Equilibrative nucleoside transporter 4 | Transporter | INHIBITOR | Ki | 5.90 | IUPHAR | ||||
Sodium/nucleoside cotransporter 1 | Transporter | INHIBITOR | Ki | 7.54 | DRUG MATRIX | ||||
Protein prune homolog | Enzyme | IC50 | 6.11 | CHEMBL | |||||
Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A | Enzyme | Ki | 6.40 | CHEMBL | |||||
Arachidonate 15-lipoxygenase | Enzyme | IC50 | 5.16 | DRUG MATRIX | |||||
Cyclic AMP-specific phosphodiesterase SSPDE4A1A | Enzyme | IC50 | 5.28 | CHEMBL | |||||
Cyclic nucleotide phosphodiesterase PDE3A | Enzyme | IC50 | 4.36 | CHEMBL | |||||
ORF 73 | Unclassified | AC50 | 5.05 | CHEMBL | |||||
Main protease (M-PRO) | Enzyme | INHIBITOR | IC50 | 6.26 | SCIENTIFIC LITERATURE |
ID | Source |
---|---|
4017884 | VUID |
N0000146237 | NUI |
D00302 | KEGG_DRUG |
4017884 | VANDF |
C0308607 | UMLSCUI |
CHEBI:4653 | CHEBI |
CHEMBL932 | ChEMBL_ID |
DB00975 | DRUGBANK_ID |
D004176 | MESH_DESCRIPTOR_UI |
3108 | PUBCHEM_CID |
4807 | IUPHAR_LIGAND_ID |
1545 | INN_ID |
64ALC7F90C | UNII |
203015 | RXNORM |
2493 | MMSL |
2527 | MMSL |
3353 | MMSL |
4619 | MMSL |
d00213 | MMSL |
000691 | NDDF |
387371005 | SNOMEDCT_US |
66859009 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Aspirin and Dipyridamole | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0093-3064 | CAPSULE, EXTENDED RELEASE | 200 mg | ORAL | ANDA | 27 sections |
Dipyridamole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1461 | TABLET, FILM COATED | 25 mg | ORAL | ANDA | 21 sections |
Dipyridamole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1462 | TABLET, FILM COATED | 50 mg | ORAL | ANDA | 21 sections |
Dipyridamole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-1463 | TABLET, FILM COATED | 75 mg | ORAL | ANDA | 21 sections |
Aggrenox | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0597-0001 | CAPSULE, EXTENDED RELEASE | 200 mg | ORAL | NDA | 29 sections |
Persantine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0597-0017 | TABLET, COATED | 25 mg | ORAL | NDA | 21 sections |
Persantine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0597-0018 | TABLET, COATED | 50 mg | ORAL | NDA | 21 sections |
Persantine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0597-0019 | TABLET, COATED | 75 mg | ORAL | NDA | 21 sections |
Dipyridamole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-2569 | INJECTION | 5 mg | INTRAVENOUS | ANDA | 19 sections |
Aspirin and Dipyridamole | HUMAN PRESCRIPTION DRUG LABEL | 2 | 16714-964 | CAPSULE, EXTENDED RELEASE | 200 mg | ORAL | ANDA | 27 sections |
Aggrenox | HUMAN PRESCRIPTION DRUG LABEL | 2 | 21695-656 | CAPSULE | 200 mg | ORAL | NDA | 17 sections |
Aspirin and Extended-Release Dipyridamole | HUMAN PRESCRIPTION DRUG LABEL | 2 | 42291-116 | CAPSULE | 200 mg | ORAL | ANDA | 26 sections |
Aspirin and Dipyridamole | HUMAN PRESCRIPTION DRUG LABEL | 2 | 43598-339 | CAPSULE, EXTENDED RELEASE | 200 mg | ORAL | ANDA | 26 sections |
Aspirin and Dipyridamole Extended Release | Human Prescription Drug Label | 2 | 47335-927 | CAPSULE | 200 mg | ORAL | ANDA | 25 sections |
Aspirin and Extended - Release Dipyridamole Capsules, 25 mg / 200 mg | HUMAN PRESCRIPTION DRUG LABEL | 2 | 49884-007 | CAPSULE | 200 mg | ORAL | ANDA | 25 sections |
Aspirin and Extended-Release Dipyridamole | HUMAN PRESCRIPTION DRUG LABEL | 2 | 51407-271 | CAPSULE, EXTENDED RELEASE | 200 mg | ORAL | ANDA | 19 sections |
DIPYRIDAMOLE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51662-1447 | INJECTION | 5 mg | INTRAVENOUS | ANDA | 11 sections |
Dipyridamole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51808-204 | SOLUTION | 5 mg | INTRAVENOUS | Unapproved drug other | 7 sections |
Dipyridamole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 52584-569 | INJECTION | 5 mg | INTRAVENOUS | ANDA | 11 sections |
Aggrenox | HUMAN PRESCRIPTION DRUG LABEL | 2 | 54868-5143 | CAPSULE | 200 mg | ORAL | NDA | 19 sections |
Aspirin and Extended-Release Dipyridamole | HUMAN PRESCRIPTION DRUG LABEL | 2 | 62175-330 | CAPSULE, EXTENDED RELEASE | 200 mg | ORAL | ANDA | 19 sections |
Aspirin and Extended-Release Dipyridamole | HUMAN PRESCRIPTION DRUG LABEL | 2 | 62559-850 | CAPSULE | 200 mg | ORAL | ANDA | 26 sections |
DIPYRIDAMOLE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 64980-133 | TABLET, FILM COATED | 25 mg | ORAL | ANDA | 19 sections |
DIPYRIDAMOLE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 64980-134 | TABLET, FILM COATED | 50 mg | ORAL | ANDA | 19 sections |
DIPYRIDAMOLE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 64980-135 | TABLET, FILM COATED | 75 mg | ORAL | ANDA | 19 sections |
Aspirin and Extended-Release Dipyridamole | HUMAN PRESCRIPTION DRUG LABEL | 2 | 65162-596 | CAPSULE | 200 mg | ORAL | ANDA | 27 sections |
Dipyridamole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65841-662 | TABLET, FILM COATED | 25 mg | ORAL | ANDA | 1 sections |
Dipyridamole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65841-663 | TABLET, FILM COATED | 50 mg | ORAL | ANDA | 1 sections |
Dipyridamole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65841-664 | TABLET, FILM COATED | 75 mg | ORAL | ANDA | 1 sections |
Dipyridamole | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68151-2996 | TABLET | 25 mg | ORAL | NDA authorized generic | 17 sections |